candidato vacunal Abdala
Kingstown, December 28 (RHC)-- Cuba's anti-Covid-19 Abdala vaccine is available for the population of St. Vincent and the Grenadines, the first country of the Caribbean Community (CARICOM) to authorize the use of the drug, it was announced Tuesday.
The immunogen designed by the Center for Genetic Engineering and Biotechnology received emergency use authorization last July from the national regulatory body. It became the first of its kind in the Caribbean island and Latin America, the Ministry of Health of San Vicente reported on its Facebook page.
Abdala showed a 92.28 percent efficacy in preventing symptomatic disease and a 90 percent effectiveness in severe patients affected by the SARS-CoV-2 coronavirus.
It also revealed an increase of 99.15 percent of antibodies in volunteers aged three to 11 years and 98.28 percent in those aged 12 to 18 years participating in the Ismaelillo clinical trial in the central province of Camagüey.
On the other hand, the Ministry reminded that other vaccines such as Sputnik V and Sputnik Light from Russia, AstraZeneca (United Kingdom), and Pfizer (United States) are administered in St. Vincent and the Grenadines.
Up to December 16, 59,702 doses of immunogens against Covid-19 were applied in that country, of which 33,192 first injections and 25,262 correspond to the second application, according to the source.
